

Eohilia (budesonide)
Effective 09/01/2025

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange		Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit			<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A			
Contact Information	Medical Benefit	Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A			

Overview

Eohilia (budesonide) oral suspension is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.

Coverage Guidelines

Authorization may be granted for members new to the plan within the last 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when all of the following criteria are met:

- Member is 11 years of age or older
- Member has a diagnosis of eosinophilic esophagitis as evidenced by BOTH of the following:
 - Chronic symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, food refusal, abdominal pain, heartburn, regurgitation, chest pain, odynophagia)
 - Findings from esophageal biopsies (e.g., eosinophil-predominant inflammation)
- Member has had an inadequate response (defined as at least 2 months), intolerance or adverse reaction to at least one proton pump inhibitor OR a contraindication to all proton pump inhibitors

Limitations

- Approval will be limited to 12 weeks of treatment.
- The following quantity limits apply:

Drug Name	Quantity Limit
Eohilia	20 mL/day

References

- Bonis PAL. Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE). UpToDate. Available at. www.uptodate.com. Access 2 July 2024.
- Eohilia (budesonide) oral suspension [prescribing information]. Lexington, MA: Takeda Pharmaceuticals; February 2024.

3. Hirano I, Chan ES Rank MA, et al. AGA Institute and Joint Task Force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. *Gastroenterol.* 2020;158:1776-1786.
4. Hirano I, Collins MH, Katzka DA, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. *Clinical Gastroenterol Hepatol.* 2022;20(3):525-534.

Review History

07/10/2024 – Reviewed by P&T; Effective 10/01/2024.

08/13/2025 – Reviewed at August P&T. No clinical changes. Effective 09/01/2025.

